This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as blinatumomab, may block cancer growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.
Principal Investigator: Andrew Dalovisio, MD
Participating Physicians: Jay Brooks, M.D., Ronald Delrie, M.D., Ruben Fabrega, M.D., Sreekanth Vasireddy, M.D., Charles Wendling, M.D.
|Full Protocol Title||A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults|
Main Campus - Jefferson Highway
Baton Rouge Clinic
|Sponsor||National Cancer Institute (NCI)|
|Duration||Up to 10 years|
|Change in Care||Participating may change your care|